{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:31:46Z","timestamp":1777905106904,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>B cell depletion therapy based on rituximab in patients with RA was pioneered at University College London Hospitals\/University College London in 1998. The objective of this study was to evaluate long-term persistence of rituximab and identify factors associated with discontinuation of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective review of medical records from all rituximab-treated RA patients followed up in a dedicated clinic (1998\u20132020). Data collected included gender, disease duration, previous DMARDs, autoantibody status, age and concomitant therapy at first cycle, length of follow-up, and number of cycles. Drug survival and factors associated with drug discontinuation were analysed using Kaplan\u2013Meier survival curves, log-rank test and Cox regression analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 404 patients were included. Median disease duration and age at time of first rituximab cycle were 10 and 57\u2009years, respectively. Median total follow-up was 55\u2009months and median number of cycles five. 93.1% of patients were seropositive. Overall, 31.2% of patients stopped rituximab, with the largest reason for discontinuing being primary inefficacy (42.1%). Comparison of Kaplan\u2013Meier curves showed that rituximab drug survival was lower in seronegative patients and in patients who had previously failed at least one biologic DMARD (bDMARD). Cox regression analysis revealed that rituximab discontinuation was associated with a greater number of previous bDMARDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Many patients with RA achieve good control of their disease with repeated cycles of rituximab treatment. The most common reasons for treatment discontinuation were either primary or secondary inefficacy. Patients who were seronegative and who had previously failed other bDMARDs were more at risk of drug discontinuation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab248","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T12:40:48Z","timestamp":1616676048000},"page":"591-596","source":"Crossref","is-referenced-by-count":18,"title":["Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020"],"prefix":"10.1093","volume":"61","author":[{"given":"Caitlin","family":"Norris-Grey","sequence":"first","affiliation":[{"name":"Centre for Rheumatology Research, University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Cambridge","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research, University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Moore","sequence":"additional","affiliation":[{"name":"University College London Hospitals, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkat","family":"Reddy","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research, University College London"},{"name":"University College London Hospitals, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Leandro","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research, University College London"},{"name":"University College London Hospitals, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"2022020819080915500_keab248-B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard.62.1.15","article-title":"Contribution of patient related differences to multidrug resistance in rheumatoid arthritis","volume":"62","author":"Morgan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2022020819080915500_keab248-B2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"2022020819080915500_keab248-B3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2022020819080915500_keab248-B4","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"2022020819080915500_keab248-B5","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022020819080915500_keab248-B6"},{"key":"2022020819080915500_keab248-B7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","article-title":"Long-term persistence with rituximab in patients with rheumatoid arthritis","volume":"57","author":"Oldroyd","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022020819080915500_keab248-B8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/acr.22314","article-title":"Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology Registry","volume":"66","author":"Payet","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022020819080915500_keab248-B9","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.131279","article-title":"Long-term followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis Registry","volume":"41","author":"De Keyser","year":"2014","journal-title":"J Rheumatol"},{"key":"2022020819080915500_keab248-B10","first-page":"1","article-title":"Factors associated with long-term persistence of rituximab in rheumatoid arthritis in clinical practice: RITAR Study","volume":"155","author":"Orbis","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"2022020819080915500_keab248-B11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40266-020-00782-x","article-title":"Does older age have an impact on rituximab efficacy and safety? Results from the NOR-DMARD Register","volume":"37","author":"Mielnik","year":"2020","journal-title":"Drugs Aging"},{"key":"2022020819080915500_keab248-B12","first-page":"893","article-title":"Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study","volume":"34","author":"Vassilopoulos","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2022020819080915500_keab248-B13","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/acr.22327","article-title":"Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German Biologics Register","volume":"66","author":"Richter","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab248\/37552551\/keab248.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/2\/591\/42368719\/keab248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/2\/591\/42368719\/keab248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T19:09:45Z","timestamp":1644347385000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/2\/591\/6189044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,3,26]]},"published-print":{"date-parts":[[2022,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab248","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,3,26]]}}}